$ABBV news
The latest ABBV stock news: headlines, filings, AI summaries and sentiment for $ABBV, updated around the clock.
- AbbVie Reports Improved Facial Satisfaction Among GLP-1 Weight-Loss Medication Users
- REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement
- AbbVie and Nxera Pharma Enter $1.5 Billion Licensing Agreement for IBD Therapy
- AbbVie Inc. - 10-Q Filing
- Genmab Shares Double Following Three Successful Phase 3 Cancer Drug Trials
- AbbVie Inc. - 8-K Filing
- AbbVie Clinical Trial Shows Promising Results for Crohn's Disease Combination Therapy
- AbbVie Raises Full-Year Revenue Guidance Following Strong Immunology and Neuroscience Performance
- AbbVie Reports Strong Third Quarter Growth Driven by Skyrizi and Rinvoq
- AbbVie Reports Strong Q3 2026 Results Driven by Skyrizi and Rinvoq Growth
- AbbVie Raises Full-Year Revenue Guidance and Announces Dividend Increase
- AbbVie Reports Q3 Earnings Beat Driven by Skyrizi and Rinvoq Growth
- AbbVie Reports Q3 2026 Revenue Beat Driven by Skyrizi and Rinvoq Growth
- AbbVie Exceeds Q3 Earnings and Revenue Expectations, Raises Full-Year Guidance
- AbbVie Increases Quarterly Dividend to $1.82 Per Share
- AbbVie Inc. - 8-K Filing
- AbbVie Reports Q3 Earnings Beat and Raises Full-Year Guidance
- Major Energy and Pharmaceutical Earnings Scheduled for Friday Pre-Market
- Analysts Forecast Strong Q3 Earnings Growth for AbbVie Driven by Skyrizi and Rinvoq
- AbbVie Successfully Transitions Revenue from Humira to New Immunology and Neuroscience Growth Engines
- AbbVie Submits FDA Biologics License Application for Etentamig in Multiple Myeloma
- AbbVie Reports Positive Phase 3 Results for Lutikizumab in Hidradenitis Suppurativa
- Comparative Revenue Analysis of AbbVie and Bristol Myers Squibb
- Merck and AbbVie: Two High-Performing Dividend Stocks in Healthcare
- AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn's
- Johnson & Johnson Exceeds Q3 Earnings Expectations and Raises Full-Year Guidance
- Iambic Therapeutics Plans IPO with Valuation Over $800 Million
- HSBC Raises Price Target on AbbVie to $315 Amid Growth Catalysts
- Pfizer Announces $0.43 Quarterly Dividend
- AbbVie Incurs $216 Million IPR&D Expense in Q3
- AbbVie Inc. - 8-K Filing
- Genmab and AbbVie Report Positive Phase 3 Trial Results for Epkinly in B-cell Lymphoma
- FDA Approves Additional Manufacturing Capacity for Alvotech's Biosimilar Simlandi
- AbbVie Included in New 340B Rebate Pilot Program
- AbbVie Receives FDA Approval for Parkinson's Treatment Juvmo
- AbbVie's Rinvoq Shows Continued Repigmentation in Patients with Non-Segmental Vitiligo Through Week 76
- AbbVie's investigational obesity drug shows up to 9.8% weight loss in Phase 1 trial
- AbbVie's Juvmo Approved by FDA for Treatment of Parkinson's Disease
- Johnson & Johnson Outperforms Peers Despite Slower Revenue Growth
- AbbVie receives EU approval for Rinvoq to treat pediatric arthritis
- ADARx Pharmaceuticals Targets $1.74 Billion Valuation with Upcoming US IPO
- AbbVie partners with Iambic Therapeutics on multi-year AI drug discovery collaboration
- AbbVie's Migraine Drug Qulipta Achieves Key Clinical Milestone
- AbbVie Reports Strong Phase 3 Results for Myeloma Treatment Etentamig
- Eight Biotech Companies Testing Investor Appetite for Upcoming IPOs
- Ken Griffin's Citadel Invests Heavily in AbbVie Amid Market Uncertainty
- Billionaire Israel 'Izzy' Englander Increases Stake in AbbVie and Invests in SpaceX
- AbbVie's Reduced Commentary on Humira Amid Biosimilar Competition
- High-Grade Debt Issuance Surpasses $57 Billion in Post-Labor Day Surge
- Eli Lilly's Supply Constraints and Market Impact